SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. today announced the initiation of a Phase IIa clinical trial of KD7040, an inducible nitric oxide synthase (iNOS) inhibitor formulated as a topical gel, for the treatment of postherpetic neuralgia (PHN).